Quick Answer
Gain Therapeutics, Inc. reported Diluted EPS of $0.61 per share (loss) for fiscal year 2025.
Gain Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.61 | +31.5% |
| 2024 | -$0.89 | +48.0% |
| 2023 | -$1.71 | -15.5% |
| 2022 | -$1.48 | -8.0% |
| 2021 | -$1.37 | -3.0% |
| 2020 | -$1.33 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.15 | +11.8% | +21.1% |
| June 30, 2025 | -$0.19 | +54.8% | -18.8% |
| March 31, 2025 | -$0.16 | +27.3% | +5.9% |
| September 30, 2024 | -$0.17 | +54.1% | +59.5% |
| June 30, 2024 | -$0.42 | +32.3% | -90.9% |
| March 31, 2024 | -$0.22 | +48.8% | +40.5% |
| September 30, 2023 | -$0.37 | +2.6% | +40.3% |
| June 30, 2023 | -$0.62 | -44.2% | -44.2% |
- Gain Therapeutics, Inc. showed an increase of +31.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Gain Therapeutics, Inc.’s diluted eps has grown by 54.1% (from $1.33 per share (loss) to $0.61 per share (loss)).
- The most recent figure is from Gain Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: